The demand from both new and current investors highlights confidence in CytoDyn’s clinical progress and its versatile development strategy in immuno-oncology, exploring a number of potential roles for ...

A federal jury Monday convicted the former chief executive for local biotechnology company CytoDyn, along with the head of the company’s regulatory agent to the U.S. Food and Drug Administration, for ...

VANCOUVER, Washington, Nov. 03, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal ...

VANCOUVER, Washington, Dec. 01, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized ...

CytoDyn is a clinical-stage biotechnology company focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The $14 million Amarex had ...

(RTTNews) - CytoDyn Inc. (CYDY.OB) has announced positive results from its preclinical studies in collaboration with SMC Laboratories, demonstrating the potential of leronlimab to reverse liver ...

(RTTNews) - CytoDyn Inc. (CYDY) has received dedicated funding from a compassionate benefactor to initiate an Expanded Access Program (EAP) for patients with triple-negative breast cancer, marking a ...

VANCOUVER, Washington, Nov. 25, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for ...